Skip to main content

Table 5 Treatment differences among the groups of stage III and stage IV long-term survivors

From: Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients

Variables

Stage III

Stage IV

Groups

3 ≤ OS < 5

5 ≤ OS (tumor +)

5 ≤ OS (tumor -): CR

P value

3 ≤ OS < 5

5 ≤ OS (tumor +)

5 ≤ OS (tumor -): CR

P value

Chemotherapy

 Treatment line No. (mean ± SD)

3.7 ± 2.0

3.7 ± 2.8

1.7 ± 1.0*

< 0.05

5.9 ± 2.5

5.5 ± 3.4

2.0 ± 1.4*

< 0.05

 Total cycle No. (include EGFR-TKI#) (mean ± SD)

16.3 ± 10.2

20.3 ± 19.6

10.2 ± 11.7

0.20

23.8 ± 13.6

25.1 ± 18.4

5.4 ± 3.5*#

< 0.05

EGFR-TKI usage

 +; no. (%)

4 (31%)

3 (25%)

0 (0%)

0.12

20 (69%)

11 (65%)

1 (20%)

0.11

 -; no. (%)

9 (69%)

9 (75%)

12 (100%)

 

9 (31%)

6 (35%)

4 (80%)

 

 EGFR-TKI line No.

0.5 ± 0.8min: 1, max: 2

0.5 ± 1.0

min: 1, max: 3

0

0.13

1.5 ± 1.3

min: 1, max: 4

1.1 ± 1.1

min: 1, max: 3

0.4 ± 0.9

min: 2, max: 2

0.15

Radiation

 Primary

  +; no. (%)

11 (85%)

8 (67%)

12 (100%)

0.09

5 (17%)

4 (24%)

2 (40%)

0.51

  -; no. (%)

2 (15%)

4 (33%)

0 (0%)

 

24 (83%)

13 (76%)

3 (60%)

 

Metastatic lesions other than brain

 +; no. (%)

1 (8%)

3 (25%)

3 (25%)

0.43

11 (38%)

5 (29%)

2 (40%)

0.82

 -; no. (%)

12 (92%)

9 (75%)

9 (75%)

 

18 (62%)

12 (71%)

3 (60%)

 

Both primary and metastatic lesions other than brain

 +; no. (%)

1 (8%)

3 (25%)

3 (25%)

0.43

2 (7%)

1 (6%)

0 (0%)

0.83

 -; no. (%)

12 (92%)

9 (75%)

9 (75%)

 

27 (93%)

16 (94%)

5 (100%)

 

Surgery

 Primary

  +; no. (%)

1 (8%)

3 (25%)

0 (0%)

0.13

2 (7%)

1 (6%)

2 (40%)

0.06

  -; no. (%)

12 (92%)

9 (75%)

12 (100%)

 

27 (93%)

16 (94%)

3 (60%)

 

Metastatic lesions other than brain

 +; no. (%)

0 (0%)

0 (0%)

0 (0%)

1.00

0 (0%)

0 (0%)

2 (40%)

< 0.05

 -; no. (%)

13 (100%)

12 (100%)

12 (100%)

 

29 (100%)

17 (100%)

3 (60%)

 

Both primary and metastatic lesions other than brain

 +; no. (%)

0 (0%)

0 (0%)

0 (0%)

1.00

0 (0%)

0 (0%)

1 (20%)

< 0.05

 -; no. (%)

13 (100%)

12 (100%)

12 (100%)

 

29 (100%)

17 (100%)

4 (80%)

 

Treatment of brain metastases

 SRT

        

 +; no. (%)

1 (8%)

3 (25%)

0 (0%)

0.13

8 (28%)

5 (29%)

1 (20%)

0.92

 -; no. (%)

12 (92%)

9 (75%)

12 (100%)

 

21 (72%)

12 (71%)

4 (80%)

 

Surgery

 +; no. (%)

0 (0%)

0 (0%)

0 (0%)

1.00

1 (3%)

1 (6%)

1 (20%)

0.35

 -; no. (%)

13 (100%)

12 (100%)

12 (100%)

 

28 (97%)

16 (94%)

4 (80%)

 

WBI

 +; no. (%)

1 (8%)

1 (8%)

0 (0%)

0.60

7 (24%)

3 (18%)

0 (0%)

0.44

 -; no. (%)

12 (92%)

11 (92%)

12 (100%)

 

22 (76%)

14 (82%)

5 (100%)

 
  1. #: One continuous EGFR-TKI usage is considered as 1 cycle, *: < 0.05 compared with the 3 ≤ OS < 5 group, #: < 0.05 compared with the 5 ≤ OS with tumor (tumor +) group, + denotes done of the treatment. -denotes not-done of the treatment. Metastatic lesions include at initial diagnosis and during treatment course.
  2. All significant P values are expressed in boldface, and not significant P values are expressed in plainface